NCT05017844 - [KSR-001-P02] Phase 2b/3 Study, Evaluate the Efficacy and Safety of KSR-001 in Patients With Dry Eye Syndrome | Biotech Hunter

Enrollment

222

Participants

Timeline

Start Date

February 18, 2020

Primary Completion Date

February 8, 2021

Study Completion Date

June 22, 2021

Conditions

Dry Eye Syndromes

Interventions

DRUG

KSR-001-04

One drop to both eyes four times a day for 12 weeks

DRUG

KSR-001-02

One drop to both eyes four times a day for 12 weeks

DRUG

KSR-001-03

One drop to both eyes four times a day for 12 weeks

Trial Locations (1)

Kukje Pharma, Seongnam